
Devonian Health Group Inc.
DHGRFiledDevonian Health Group Inc. · NYSE American · Research source · F-1/A · 2026-09-02
IPO research
Devonian Health Group Inc. filed an F-1/A for a proposed offering of up to 3,070,000 common units or pre-funded units, with NYSE American listing approval still pending.
Full source-backed summary
Devonian is pursuing a proposed NYSE American firm-commitment offering of up to 3,070,000 units at an assumed USD 7.00 per unit, but the offering remains preliminary and depends on NYSE American approval. The issuer has continuing losses, substantial clinical and regulatory execution risk, and material dilution exposure.
Devonian Health Group Inc. filed an F-1/A for a proposed offering of up to 3,070,000 common units or pre-funded units, with NYSE American listing approval still pending.
- Business and development direction
Devonian Health Group Inc.
Current business Future development
Key risks
Risk 1
The offering cannot proceed if NYSE American does not approve the listing application.
Risk 2
Botanical drug development may require additional analytical, bridging or clinical work if sourcing changes or consistency is not demonstrated.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Source-linked structured inputs are not yet available. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | ThinkEquity LLC |
IPO CAPITAL QUALITY
Basis and evidence
F-1/A · 2026-09-02
Devonian Health Group Inc. filed an F-1/A for a proposed offering of up to 3,070,000 common units or pre-funded units, with NYSE American listing approval still pending.
Offering structure
Source and calculation
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer Common Shares — base/no option | 5,850,866 | — | |
| Post-offer Common Shares — full option | 6,311,366 | — |
Basis and evidence ↗
Prospectus share summary; Common Shares to be outstanding after this offering(1); 5,850,866 Common Shares (or 6,311,366 Common Shares if the underwriters exercise the Over-Allotment Option in full) presuming full exercise of any Pre-funded Warrants issued.; selected security: Common Shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Exact input · Post-offer Common Shares — base/no option: 5,850,866
Prospectus share summary; Common Shares to be outstanding after this offering(1); 5,850,866 Common Shares (or 6,311,366 Common Shares if the underwriters exercise the Over-Allotment Option in full) presuming full exercise of any Pre-funded Warrants issued.; selected security: Common Shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Source inputs required
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-09-02
Relationship filters
Select for details · Devonian Health Group Inc.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| André P. BouletBeneficial shares | 386,039 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| André P. BouletBeneficial shares | 386,039 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Aspri Pharma Inc.Beneficial shares | 159,564 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Aspri Pharma Inc.Beneficial shares | 159,564 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Fabien Fontaine / Groupe JAFACO GestionBeneficial shares | 166,667 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Fabien Fontaine / Groupe JAFACO GestionBeneficial shares | 166,667 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Luc BuissonBeneficial shares | 10,000 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Luc BuissonBeneficial shares | 10,000 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Louis FlamandBeneficial shares | 17,619 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Louis FlamandBeneficial shares | 17,619 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Luc GrégoireBeneficial shares | 117,172 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Luc GrégoireBeneficial shares | 117,172 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| André P. BouletBeneficial ownership | — | 13.88%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| André P. BouletBeneficial ownership | — | 6.6%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Aspri Pharma Inc.Beneficial ownership | — | 5.74%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Aspri Pharma Inc.Beneficial ownership | — | 2.73%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Fabien Fontaine / Groupe JAFACO GestionBeneficial ownership | — | 5.99%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Fabien Fontaine / Groupe JAFACO GestionBeneficial ownership | — | 2.85%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Luc BuissonBeneficial ownership | — | 0.36%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Luc BuissonBeneficial ownership | — | 0.17%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Louis FlamandBeneficial ownership | — | 0.63%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Louis FlamandBeneficial ownership | — | 0.3%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Luc GrégoireBeneficial ownership | — | 4.21%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Luc GrégoireBeneficial ownership | — | 2%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Pierre LabbéBeneficial shares | 6,083 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Pierre LabbéBeneficial shares | 6,083 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Josh MuntnerBeneficial shares | 10,000 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Josh MuntnerBeneficial shares | 10,000 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Kathryn GregoryBeneficial shares | 12,035 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Kathryn GregoryBeneficial shares | 12,035 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Kira SheinermanBeneficial shares | 10,000 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Kira SheinermanBeneficial shares | 10,000 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Dennis TurpinBeneficial shares | 38,393 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| Dennis TurpinBeneficial shares | 38,393 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| All directors and executive officers as a group (9 persons)Beneficial shares | 607,341 | — | — | Common Shares Beneficially Owned Prior to this Offering; Shares |
| All directors and executive officers as a group (9 persons)Beneficial shares | 607,341 | — | — | Common Shares Beneficially Owned After this Offering; Shares |
| Pierre LabbéBeneficial ownership | — | 0.22%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Pierre LabbéBeneficial ownership | — | 0.1%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Josh MuntnerBeneficial ownership | — | 0.36%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Josh MuntnerBeneficial ownership | — | 0.17%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Kathryn GregoryBeneficial ownership | — | 0.43%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Kathryn GregoryBeneficial ownership | — | 0.21%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Kira SheinermanBeneficial ownership | — | 0.36%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Kira SheinermanBeneficial ownership | — | 0.17%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Dennis TurpinBeneficial ownership | — | 1.38%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| Dennis TurpinBeneficial ownership | — | 0.66%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| All directors and executive officers as a group (9 persons)Beneficial ownership | — | 21.84%Beneficial | — | Common Shares Beneficially Owned Prior to this Offering; % |
| All directors and executive officers as a group (9 persons)Beneficial ownership | — | 10.38%Beneficial | — | Common Shares Beneficially Owned After this Offering; % |
| Common Shareper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; Common Share; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source class-history inconsistency: October 7, 2024 amendment states that Multiple Voting, Exchangeable Voting and Subordinate Voting classes were repealed, while a later paragraph still refers to six votes for Multiple Voting Shares; this does not establish current outstanding Multiple Voting Shares or a six-vote Common Share rate |
Source and calculation ↗
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: André P. Boulet(1)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: André P. Boulet(1)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Aspri Pharma Inc.
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Aspri Pharma Inc.
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Fabien Fontaine / Groupe JAFACO Gestion
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Fabien Fontaine / Groupe JAFACO Gestion
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Luc Buisson(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Luc Buisson(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Louis Flamand(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Louis Flamand(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Luc Grégoire(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Luc Grégoire(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: André P. Boulet(1)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: André P. Boulet(1)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Aspri Pharma Inc.
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Aspri Pharma Inc.
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Fabien Fontaine / Groupe JAFACO Gestion
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Fabien Fontaine / Groupe JAFACO Gestion
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Luc Buisson(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Luc Buisson(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Louis Flamand(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Louis Flamand(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Luc Grégoire(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Luc Grégoire(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Pierre Labbé(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Pierre Labbé(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Josh Muntner(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Josh Muntner(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Kathryn Gregory(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Kathryn Gregory(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Kira Sheinerman(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Kira Sheinerman(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: Dennis Turpin(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: Dennis Turpin(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; Shares; source holder: All directors and executive officers as a group (9 persons)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; Shares; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; Shares; source holder: All directors and executive officers as a group (9 persons)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Pierre Labbé(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Pierre Labbé(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Josh Muntner(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Josh Muntner(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Kathryn Gregory(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Kathryn Gregory(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Kira Sheinerman(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Kira Sheinerman(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: Dennis Turpin(2)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: Dennis Turpin(2)
Exact source ownership column: Common Shares Beneficially Owned Prior to this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned Prior to this Offering; %; source holder: All directors and executive officers as a group (9 persons)
Exact source ownership column: Common Shares Beneficially Owned After this Offering; %; holders may overlap; not an additive partition
Raw source column: Common Shares Beneficially Owned After this Offering; %; source holder: All directors and executive officers as a group (9 persons)
Literal source per-share voting entitlement; Common Share; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source class-history inconsistency: October 7, 2024 amendment states that Multiple Voting, Exchangeable Voting and Subordinate Voting classes were repealed, while a later paragraph still refers to six votes for Multiple Voting Shares; this does not establish current outstanding Multiple Voting Shares or a six-vote Common Share rate
The Corporation’s authorized capital is made up of an unlimited number of Common Shares, without par value with voting rights of one vote per Common Share. The Warrants being sold in the offering will be in Warrants will be issued in electronic book-entry form to the investors and the warrant agent Continental Stock Transfer & Trust. Source context: On October 7, 2024, the Company announced that it had amended its articles of amalgamation, in accordance with the approval by the shareholders at the Annual General and Special Meeting held on February 20, 2024. The amended articles created a new class of shares, consisting of an unlimited number of Common Shares which carries one vote per Common Share, converted each existing issued and outstanding Subordinate Voting Share into Common Shares, and repealed the following classes of shares of the Company and the rights, privileges, restrictions and conditions attached thereto: (i) an unlimited number of Multiple Voting of the Company, (ii) an unlimited number of Exchangeable Voting Shares of the Company; and (iii) an unlimited number of Subordinate Voting Shares of the Company. Source context: Holders of Common Shares are entitled to receive notice of any meeting of shareholders of the Company; to attend and to cast one vote per share at such meetings (each Multiple Voting Share shall entitle their holders to six votes). Holders of Common Shares are also entitled to receive on a pro rata basis such dividends, if any, as and when declared by the Board of Directors at its discretion from funds legally available therefor and upon
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal month restriction; after date of the offering; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| Our directors and executive officersAfter date of the offering · Source conditions apply | 6 months |
| WeAfter date of the offering · Source conditions apply | 3 months |
Source and calculation
Our directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information.
SEC lock-up paragraph; source 309362:310189; SHA256 a9035606293cc163305360de030d76cd59b0e951edb63755cf25d5bc23b3f59f ↗Our directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information.
SEC lock-up paragraph; source 309362:310189; SHA256 a9035606293cc163305360de030d76cd59b0e951edb63755cf25d5bc23b3f59f ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
date of the offering
- WeOur directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information.
- Our directors and executive officersOur directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information.
| Holder / event | Term / date | Conditions |
|---|---|---|
| Our directors and executive officers | 6 months | Our directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information. |
| We | 3 months | Our directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information. |
Basis and evidence
Our directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information.
SEC lock-up paragraph; source 309362:310189; SHA256 a9035606293cc163305360de030d76cd59b0e951edb63755cf25d5bc23b3f59f ↗Our directors and executive officers have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six months from the date of the offering. We have agreed with the underwriters to not offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of three months from the date of the offering. See Underwriting for additional information.
SEC lock-up paragraph; source 309362:310189; SHA256 a9035606293cc163305360de030d76cd59b0e951edb63755cf25d5bc23b3f59f ↗Financial quality
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2025-07-31 · Consolidated | $6,983,620 |
| Cash and cash equivalents2024-07-31 · Consolidated | $9,862,511 |
| Cash and cash equivalents2026-04-30 · Consolidated · Unaudited | CAD 719,932 |
| Cash and cash equivalents2025-07-31 · Consolidated · Unaudited | CAD 6,983,620 |
Basis and evidence
Financial quality and runway
Financial quality and runway
Financial statements use CAD and IFRS. 2025 revenue was CAD 23.59 million and net loss CAD 6.01 million; nine-month 2026 unaudited revenue was CAD 1.72 million and net loss CAD 5.74 million.
EvidenceFinancial review 12025 distribution revenue increased from CAD 19.31 million in 2024 to CAD 23.59 million, while net loss widened largely because of impairment charges.
+
2025 distribution revenue increased from CAD 19.31 million in 2024 to CAD 23.59 million, while net loss widened largely because of impairment charges.
EvidenceFinancial review 2The supplied evidence does not establish current cash runway or going-concern status.
+
The supplied evidence does not establish current cash runway or going-concern status.
MATERIAL CHANGES
The latest material signals and their investor impact are shown below.
Why it mattersThe filing is now Amendment No. 1 under Registration Statement No. 333-297734; no change in the basic offering size is shown in the supplied excerpts.
Evidence · Cover and opening disclosureWhy it mattersThe current filing identifies the proposed NYSE American warrant symbol as DHGRWS, compared with DHGRW in the previous filing.
Evidence · Cover and opening disclosureWhy it mattersThe current filing updates the TSXV/OTCQB market-price date and beneficial-ownership reference date; the supplied evidence does not establish a substantive ownership change.
Evidence · Cover and opening disclosureF-1/A0001104659-26-104757 ↗
Loading filing history…